ACADIA Pharmaceuticals

ACAD · NASDAQ

$20.44+$0.64 (+3.23%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $19.80

Latest news

Press releaseOct 15, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Press releaseOct 13, 5:08 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Press releaseOct 1, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Press releaseSep 29, 5:29 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NewsSep 28, 4:15 PM ET
Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”
Press releaseSep 28, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
NewsSep 24, 1:43 PM ETVandana Singh
Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis
NewsSep 24, 12:02 PM ETAvi Kapoor
Crude Oil Rises Over 4%; Darden Earnings Miss Views
Press releaseSep 24, 7:00 AM ETBusiness Wire
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Press releaseAug 24, 3:01 AM ETBusiness Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
NewsAug 4, 4:12 PM ET
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate
Press releaseAug 4, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Press releaseJul 30, 5:57 PM ETBusiness Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
Press releaseJul 20, 9:05 AM ETBusiness Wire
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Press releaseJul 15, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Press releaseJul 6, 9:04 AM ETBusiness Wire
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
NewsJun 26, 1:47 PM ETVandana Singh
Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy
NewsJun 26, 12:17 PM ETAvi Kapoor
Crude Oil Falls 4%; US Consumer Sentiment Rises In June
NewsJun 26, 10:18 AM ETAvi Kapoor
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
NewsJun 26, 8:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseJun 26, 6:49 AM ETBusiness Wire
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
NewsMay 6, 4:16 PM ET
ACADIA Pharmaceuticals Q1 EPS $0.02 Misses $0.05 Estimate, Sales $268.062M Miss $280.710M Estimate
Press releaseMay 6, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Press releaseApr 30, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Press releaseApr 28, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Press releaseApr 17, 9:05 AM ETBusiness Wire
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
Press releaseApr 15, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
NewsApr 7, 9:10 AM ET
Acadia Pharmaceuticals Launches DAYBUE STIX, New Powder Trofinetide Formulation For Flexible, Patient-Centered Rett Syndrome Treatment In U.S.
Press releaseApr 7, 9:05 AM ETBusiness Wire
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Press releaseMar 12, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Press releaseMar 3, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Press releaseMar 2, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
NewsFeb 25, 5:19 PM ET
ACADIA Pharmaceuticals Q4 Adj. EPS $0.14 Beats $0.13 Estimate, Sales $283.989M Miss $292.461M Estimate
NewsFeb 25, 6:11 AM ET
Earnings Scheduled For February 25, 2026
Press releaseFeb 23, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
NewsFeb 3, 12:44 PM ETVandana Singh
EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug
Press releaseFeb 2, 4:05 PM ETBusiness Wire
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
NewsSep 24, 1:44 PM ETHenry Khederian
What's Going On With ACADIA Pharmaceuticals Stock?

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041

Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis

Crude Oil Rises Over 4%; Darden Earnings Miss Views

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M Estimate

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference

Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

Acadia Pharma Stock Jumps After European Panel Reverses Course On Rett Syndrome Therapy

Crude Oil Falls 4%; US Consumer Sentiment Rises In June

Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday

12 Health Care Stocks Moving In Friday's Pre-Market Session

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

Earnings Scheduled For May 6, 2026

ACADIA Pharmaceuticals Q1 EPS $0.02 Misses $0.05 Estimate, Sales $268.062M Miss $280.710M Estimate

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Acadia Pharmaceuticals Launches DAYBUE STIX, New Powder Trofinetide Formulation For Flexible, Patient-Centered Rett Syndrome Treatment In U.S.

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

ACADIA Pharmaceuticals Q4 Adj. EPS $0.14 Beats $0.13 Estimate, Sales $283.989M Miss $292.461M Estimate

Earnings Scheduled For February 25, 2026

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

What's Going On With ACADIA Pharmaceuticals Stock?